Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiff Oncology (CRDF) Amortization of Deferred Charges (2016 - 2017)

Cardiff Oncology's Amortization of Deferred Charges history spans 7 years, with the latest figure at -$70657.0 for Q2 2017.

  • For Q2 2017, Amortization of Deferred Charges fell 5.95% year-over-year to -$70657.0; the TTM value through Jun 2017 reached -$404502.0, down 153.42%, while the annual FY2016 figure was -$201037.0, N/A changed from the prior year.
  • Amortization of Deferred Charges for Q2 2017 was -$70657.0 at Cardiff Oncology, down from -$66119.0 in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $2.3 million in Q2 2013 and bottomed at -$201037.0 in Q4 2016.
  • The 5-year median for Amortization of Deferred Charges is $411943.5 (2013), against an average of $503730.9.
  • The largest YoY upside for Amortization of Deferred Charges was 209.87% in 2013 against a maximum downside of 67.73% in 2013.
  • A 5-year view of Amortization of Deferred Charges shows it stood at $757198.0 in 2013, then changed by 0.0% to $757198.0 in 2014, then plummeted by 91.19% to $66689.0 in 2015, then crashed by 401.45% to -$201037.0 in 2016, then skyrocketed by 64.85% to -$70657.0 in 2017.
  • Per Business Quant, the three most recent readings for CRDF's Amortization of Deferred Charges are -$70657.0 (Q2 2017), -$66119.0 (Q1 2017), and -$201037.0 (Q4 2016).